 |
 |
Ron: Re: adverse effects of carbidopa . . . You recently posted some info on carbidopa and its combination with levodopa to enhance the availability of levodopa to the brain. . . and suggested: "I do believe there is a need to study the potential problem of over-dosing with carbidopa." What about the pharmadynamics of Benserazide? This is the ingrediant in Madopar (used outside U.S.A.) insted of carbidopa. Is the optimum dose the same - 70 to 100 mg per day? Is there any clinical data? Stephan Schwartz 53/7 <[log in to unmask]>